Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.85 USD
+0.14 (8.19%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.88 +0.03 (1.62%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXDX 1.85 +0.14(8.19%)
Will AXDX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AXDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXDX
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial
AXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
Other News for AXDX
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc? System
Accelerate Diagnostics announces FDA clearance of Accelerate Arc system
US settles with billionaire Carl Icahn for using company to secure personal loans worth billions
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
AXDX Stock Earnings: Accelerate Diagnostics Beats EPS, Misses Revenue for Q2 2024